1. Targeted Delivery of Iron Oxide Nanoparticle-Loaded Human Embryonic Stem Cell-Derived Spherical Neural Masses for Treating Intracerebral Hemorrhage.
- Author
-
Kang MK, Kim TJ, Kim YJ, Kang L, Kim J, Lee N, Hyeon T, Lim MS, Mo HJ, Shin JH, Ko SB, and Yoon BW
- Subjects
- Animals, Behavior Rating Scale, Brain pathology, Brain radiation effects, Cell Survival drug effects, Cell Survival radiation effects, Cerebral Hemorrhage radiotherapy, Cyclooxygenase 2 metabolism, Cytokines metabolism, Humans, Inflammation drug therapy, Inflammation radiotherapy, Injections, Intravenous, Male, Neural Stem Cells metabolism, Rats, Rats, Sprague-Dawley, Recovery of Function physiology, Spheroids, Cellular metabolism, Brain drug effects, Cerebral Hemorrhage drug therapy, Human Embryonic Stem Cells metabolism, Magnetic Field Therapy methods, Magnetic Iron Oxide Nanoparticles chemistry, Recovery of Function drug effects
- Abstract
This study evaluated the potential of iron oxide nanoparticle-loaded human embryonic stem cell (ESC)-derived spherical neural masses (SNMs) to improve the transportation of stem cells to the brain, ameliorate brain damage from intracerebral hemorrhage (ICH), and recover the functional status after ICH under an external magnetic field of a magnet attached to a helmet. At 24 h after induction of ICH, rats were randomly separated into three experimental groups: ICH with injection of phosphate-buffered saline (PBS group), ICH with intravenous injection of magnetosome-like ferrimagnetic iron oxide nanocubes (FION)-labeled SNMs (SNMs* group), and ICH with intravenous injection of FION-labeled SNMs followed by three days of external magnetic field exposure for targeted delivery by a magnet-embedded helmet (SNMs*+Helmet group). On day 3 after ICH induction, an increased Prussian blue-stained area and decreased swelling volume were observed in the SNMs*+Helmet group compared with that of the other groups. A significantly decreased recruitment of macrophages and neutrophils and a downregulation of pro-inflammatory cytokines followed by improved neurological function three days after ICH were observed in the SNMs*+Helmet group. Hemispheric atrophy at six weeks after ICH was significantly decreased in the SNMs*+Helmet group compared with that of the PBS group. In conclusion, we have developed a targeted delivery system using FION tagged to stem cells and a magnet-embedded helmet. The targeted delivery of SNMs might have the potential for developing novel therapeutic strategies for ICH.
- Published
- 2020
- Full Text
- View/download PDF